Detail akcie Cyclerion Therp Rg online

Business Summary: Cyclerion Therapeutics, Inc. is a biopharmaceutical company dedicated to identifying, developing, and delivering therapies for central nervous system (CNS) diseases. The Company is focused on building a pipeline with therapeutics to treat certain neuropsychiatric diseases. It is focused on an individualized therapy for treatment-resistant depression (TRD) - a condition with significant unmet medical need. Its assets include Olinciguat and Praliciguat. The Company has entered into an exclusive license option agreement for its vascular soluble guanylate cyclase (sGC) stimulator, olinciguat. Praliciguat is an oral, once-daily, systemic sGC stimulator that is licensed to Akeibia Therapeutics, Inc and is being advanced in rare kidney disease.
Financial Summary: BRIEF: For the nine months ended 30 September 2025, Cyclerion Therapeutics Inc revenues increased from $194K to $1M. Net loss decreased 24% to $2.7M. Revenues reflect an increase in demand for the Company's products and services due to favorable market conditions. Lower net loss reflects Stock-based Compensation in SGA decrease of 26% to $318K (expense), Stock-based Compensation in R&D decrease of 62% to $28K (expense).